Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Tuesday's Analyst Blog:

Durect to Rebound from Setback

Durect Corp. (NASDAQ: DRRX) utilizes 6 proprietary drug delivery technologies to develop pharmaceutical systems that enhance treatment capabilities in the areas of chronic pain, cardiovascular diseases, and central nervous system disorders.

The company recently received disappointing news when its lead pipeline candidate, Remoxy, failed to receive FDA approval in December 2008. While this news is a setback for the company, we believe that the product will ultimately receive approval and should see significant demand due to its ability to reduce the potential of drug abuse / misuse. Meanwhile, we remain optimistic on the remaining candidates in Durect's pipeline which consists of three candidates in phase II development.

BT Group Looks to US Market

BT Group Plc (NYSE: BT) reported 2Q09 results with in-line revenues and lower than expected earnings. The company is moving ahead with the expansion of its 21CN network.

The company recently announced plans to invest £1.5 billion to make fiber-based, super-fast broadband available to as many as 10 million homes in the UK by 2012. BT Global continues to execute well, winning deals valued at £8.4 billion in the trailing-12-month period. The company has reported slightly lower EBITDA margins due lower EBITDA of Global Services while pricing pressure is causing traditional revenues to decline.

Canon Target Upped a Click

Canon Inc. (NYSE: CAJ) is one of the world's leading makers of office equipment, cameras, and optical products. The company's first nine-month results were hurt by the economic slowdown in the developed countries triggered by a financial crisis, a strong yen appreciation, and weak consumer spending. Moreover, the company reduced its guidance for the full year 2008.

We lower our estimates for fiscal 2009 due to the macroeconomic environment.